文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

淋巴结转移负荷作为晚期非小细胞肺癌预后指标的真实世界研究

Lymph nodes metastatic burden as a prognosticator for advanced non-small cell lung cancer: a real-world study.

作者信息

Chen Zhangxuan, Zhang Qingfeng, Xiong Lei, Meng Yunchang, Yao Yang, Wu Ranpu, Li Xinjing, Wang Bingxue, Sun Jiajie, Gong Yanzhuo, Liu Hongbing, Shen Yi

机构信息

Department of Respiratory and Critical Care Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.

Department of Cardiothoracic Surgery, Jinling Hospital, Jinling Clinical Medical School, Nanjing Medical University, Nanjing, China.

出版信息

J Thorac Dis. 2025 Jul 31;17(7):4501-4511. doi: 10.21037/jtd-2024-2201. Epub 2025 Jul 8.


DOI:10.21037/jtd-2024-2201
PMID:40809212
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12340286/
Abstract

BACKGROUND: Current nodal classification inadequately predicts outcomes for advanced non-small cell lung cancer (NSCLC) patients. We investigated whether metastatic lymph node characteristics could improve prognostic accuracy. METHODS: We retrospectively analyzed 339 patients with advanced NSCLC who received immunotherapy as first-line treatment. Lymph node imaging was performed using computed tomography (CT), and the X-tile software was employed to determine optimal cutoff values for lymph node size and number. Prognostic factors were assessed using Kaplan-Meier survival curves and multivariate Cox regression analysis. The predictive accuracy of various N-staging was evaluated through time-dependent receiver operating characteristic (ROC) curves. RESULTS: The optimal cutoff values for lymph node size and number were 1.60 cm and 3, respectively. Kaplan-Meier analysis indicated that size, number, and fusion of metastatic lymph nodes were associated with worse overall survival (OS) in advanced NSCLC patients {hazard ratio (HR) [95% confidence interval (CI)]: 2.179 (1.432-3.316), 1.859 (1.226-2.821), and 3.635 (1.796-7.358)}. Multivariate Cox regression analysis identified lymph node size [HR (95% CI): 6.21 (1.19-32.25)] and fusion [HR (95% CI): 3.20 (1.32-7.75)] as independent prognostic factors for OS. Incorporating lymph node size into the conventional N-staging system improved prognostic accuracy, with a 3-year area under the curve (AUC) of 0.651 (95% CI: 0.535-0.767). CONCLUSIONS: Lymph node size serves as a valuable indicator of tumor invasion and can enhance the existing N-staging system for more accurate prognosis prediction for more accurate prognosis prediction in advanced NSCLC.

摘要

背景:目前的淋巴结分类不足以预测晚期非小细胞肺癌(NSCLC)患者的预后。我们研究了转移性淋巴结特征是否能提高预后准确性。 方法:我们回顾性分析了339例接受免疫治疗作为一线治疗的晚期NSCLC患者。使用计算机断层扫描(CT)进行淋巴结成像,并采用X-tile软件确定淋巴结大小和数量的最佳截断值。使用Kaplan-Meier生存曲线和多变量Cox回归分析评估预后因素。通过时间依赖性受试者工作特征(ROC)曲线评估各种N分期的预测准确性。 结果:淋巴结大小和数量的最佳截断值分别为1.60 cm和3。Kaplan-Meier分析表明,转移性淋巴结的大小、数量和融合与晚期NSCLC患者较差的总生存期(OS)相关{风险比(HR)[95%置信区间(CI)]:2.179(1.432-3.316)、1.859(1.226-2.821)和3.635(1.796-7.358)}。多变量Cox回归分析确定淋巴结大小[HR(95%CI):6.21(1.19-32.25)]和融合[HR(95%CI):3.20(1.32-7.75)]是OS的独立预后因素。将淋巴结大小纳入传统N分期系统可提高预后准确性,3年曲线下面积(AUC)为0.651(95%CI:0.535-0.767)。 结论:淋巴结大小是肿瘤侵袭的重要指标,可增强现有的N分期系统,以便更准确地预测晚期NSCLC的预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0d9/12340286/fca9dd69a8c5/jtd-17-07-4501-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0d9/12340286/5efefc1f4419/jtd-17-07-4501-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0d9/12340286/3f060aa93a89/jtd-17-07-4501-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0d9/12340286/935b6302a50c/jtd-17-07-4501-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0d9/12340286/3dbd8b247a67/jtd-17-07-4501-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0d9/12340286/fca9dd69a8c5/jtd-17-07-4501-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0d9/12340286/5efefc1f4419/jtd-17-07-4501-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0d9/12340286/3f060aa93a89/jtd-17-07-4501-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0d9/12340286/935b6302a50c/jtd-17-07-4501-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0d9/12340286/3dbd8b247a67/jtd-17-07-4501-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0d9/12340286/fca9dd69a8c5/jtd-17-07-4501-f5.jpg

相似文献

[1]
Lymph nodes metastatic burden as a prognosticator for advanced non-small cell lung cancer: a real-world study.

J Thorac Dis. 2025-7-31

[2]
PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer.

Cochrane Database Syst Rev. 2014-11-13

[3]
Lymph node ratio emerges as a pivotal prognostic determinant for cancer-specific survival amidst individuals diagnosed with stage N1 and N2 non-small cell lung carcinoma: A population-based retrospective cohort study.

Medicine (Baltimore). 2025-4-18

[4]
Sublobar resection is non-inferior to lobectomy in octogenarians and older with stage Ia non‑small cell lung cancer.

Transl Cancer Res. 2025-5-30

[5]
Rationality of FIGO 2018 IIIC cervical cancer according to local tumor and pelvic lymph node metastatic extent-a cohort study.

BMC Womens Health. 2025-7-4

[6]
Development and validation of a prognostic model for overall survival in pN0 esophageal cancer patients after neoadjuvant chemotherapy: a SEER database-based study.

J Thorac Dis. 2025-5-30

[7]
Diagnostic accuracy of endoscopic ultrasonography (EUS) for the preoperative locoregional staging of primary gastric cancer.

Cochrane Database Syst Rev. 2015-2-6

[8]
CT Scans Understage Lymph Nodes in Gastric and Gastroesophageal Adenocarcinoma.

J Surg Oncol. 2025-6

[9]
Impact of first-line chemoimmunotherapy with or without radiotherapy on the prognosis of patients with locally advanced or metastatic esophageal squamous cell carcinoma: a multicenter, real-world, retrospective cohort study from China (NCT06478355).

Front Immunol. 2025-7-28

[10]
Development and validation of nomograms for predicting survival of locally advanced rectosigmoid junction cancer patients: a SEER database analysis.

Transl Cancer Res. 2025-5-30

本文引用的文献

[1]
The Proposed Ninth Edition TNM Classification of Lung Cancer.

Chest. 2024-10

[2]
The number of metastatic lymph nodes is more predictive of prognosis than location-based N stage for nonsmall cell lung cancer: a retrospective cohort study.

Int J Surg. 2023-12-1

[3]
Comparative analysis of methodologies for predicting overall survival in patients with non-small cell lung cancer based on the number and rate of resected positive lymph nodes: A study based on the SEER database for 2010 through 2019.

Clin Respir J. 2023-11

[4]
Endosonography With or Without Confirmatory Mediastinoscopy for Resectable Lung Cancer: A Randomized Clinical Trial.

J Clin Oncol. 2023-8-1

[5]
Dynamic CD8 T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes.

Cell. 2023-3-16

[6]
Immunotherapy in Lung Cancer: Current Landscape and Future Directions.

Front Immunol. 2022

[7]
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

CA Cancer J Clin. 2021-5

[8]
Lung Cancer in People's Republic of China.

J Thorac Oncol. 2020-10

[9]
Cancer treatment and survivorship statistics, 2019.

CA Cancer J Clin. 2019-6-11

[10]
Prognostic Impact of the Number of Metastatic Lymph Nodes on the Eighth Edition of the TNM Classification of NSCLC.

J Thorac Oncol. 2019-5-2

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索